The main pharmacological effect of anti-heart failure drugs is to address heart failure caused by reduced or impaired myocardial contractile function.
| NO. | PubChem ID | CAS Number | Molecular Name | Efficacy | Efficacy_Chinese |
|---|---|---|---|---|---|
| 81 | 3082648 | 0 | 3,5-dihydroxy-6,6-dimethyl-2-(2-methylpropanoyl)-4-[[2,4,6-trihydroxy-3-methyl-5-(2-methylpropanoyl)phenyl]methyl]cyclohexa-2,4-dien-1-one | anti-heart failure | 抗心力衰竭 |
| 82 | 3819217 | 0 | 8-[(3,3-dimethyloxiran-2-yl)methyl]-7-methoxychromen-2-one | anti-heart failure | 抗心力衰竭 |
| 83 | 4490287 | 53962-20-2 | [6-hydroxy-7-(hydroxymethyl)-4-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-1-yl] 3-methylbutanoate | anti-heart failure | 抗心力衰竭 |
| 84 | 5089887 | 0 | [1,18,19,23,23-pentahydroxy-2,5,15-trioxo-10,11-bis[(3,4,5-trihydroxybenzoyl)oxy]-6,9,14,24-tetraoxapentacyclo[18.3.1.04,22.08,13.016,21]tetracosa-3,16,18,20-tetraen-12-yl] 3,4,5-trihydroxybenzoate | anti-heart failure | 抗心力衰竭 |
| 85 | 5281647 | 4773-96-0 | 1,3,6,7-tetrahydroxy-2-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one | anti-heart failure | 抗心力衰竭 |
| 86 | 5281692 | 490-31-3 | 3,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromen-4-one | anti-heart failure | 抗心力衰竭 |
| 87 | 5281800 | 61276-17-3 | [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | anti-heart failure | 抗心力衰竭 |
| 88 | 5315422 | 0 | 7-methoxy-2,2,6-trimethylpyrano[3,2-c]quinolin-5-one | anti-heart failure | 抗心力衰竭 |
| 89 | 5315862 | 0 | (1Z)-1-butylidene-8-hydroxyisochromen-4-one | anti-heart failure | 抗心力衰竭 |
| 90 | 5316141 | 0 | 4-methoxy-5-prop-2-enyl-1,3-benzodioxole | anti-heart failure | 抗心力衰竭 |